Photo by theyshane from unsplash
: In 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on data from two trials conducted… Click to show full abstract
: In 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on data from two trials conducted in rheumatoid arthritis and ankylosing spondylitis. The same year, our Society published a position statement that was later reviewed.
Keywords:
position statement;
position;
update sepd;
sepd position;
statement use
Journal Title: Revista Espanola De Enfermedades Digestivas
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Revista Espanola De Enfermedades Digestivas
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!